Distinct Bile Acid Signature in Parkinson's Disease With Mild Cognitive Impairment

Kun Nie; Yanyi Li; Jiahui Zhang; Yuyuan Gao; Yihui Qiu; Rong Gan; Yuhu Zhang; Lijuan Wang

doi:10.3389/fneur.2022.897867

Distinct Bile Acid Signature in Parkinson's Disease With Mild Cognitive Impairment

Front Neurol. 2022 Jul 4:13:897867. doi: 10.3389/fneur.2022.897867. eCollection 2022.

Authors

Kun Nie¹, Yanyi Li^{1

2}, Jiahui Zhang¹, Yuyuan Gao¹, Yihui Qiu¹, Rong Gan¹, Yuhu Zhang¹, Lijuan Wang¹

Affiliations

¹ Department of Neurology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong Neuroscience Institute, Guangzhou, China.
² Shantou University Medical College, Shantou, China.

Abstract

Backgrounds: Bile acid (BA) plays a crucial role in various neurodegenerative diseases, including Parkinson's disease (PD). However, no clinical evidence supports BA's potential role in patients with PD with mild cognitive impairment (PD-MCI).

Objectives: This study aimed at investigating the differential BA profile between patients with PD-MCI and those with normal cognitive function (PD-NC).

Methods: Ultra-high performance liquid chromatography-MS/MS was applied for BA quantitation. After between-group differences of the BA profile were addressed, orthogonal projections to latent structures-discriminant analysis (OPLS-DA) and the area under the receiver-operating-characteristic curve (AUC-ROC) were implemented for further verification.

Results: Lower levels of chenodeoxycholic acid (CDCA), cholic acid (CA), and ursodeoxycholic acid (UDCA) were significantly associated with PD-MCI (p < 0.01 for both; VIP ≈ 2.67, 1.66, and 1.26, respectively). AUC-ROC were 78.1, 74.2, and 74.5% for CDCA, CA, and UDCA, respectively.

Conclusion: CA, CDCA, and UDCA might be distinct BA signatures for patients with PD-MCI.

Keywords: Parkinson's disease; bile acid metabolites; chenodeoxycholic acid; cholic acid; mild cognitive impairment; ursodeoxycholic acid.